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Abstract: Despite the development of novel treatments in the past 15 years, many blood cancers
still remain ultimately fatal and difficult to treat, particularly acute myeloid leukaemia (AML)
and multiple myeloma (MM). While significant progress has been made characterising small-scale
genetic mutations and larger-scale chromosomal translocations that contribute to the development of
various blood cancers, less is understood about the complex microenvironment of the bone marrow
(BM), which is known to be a key player in the pathogenesis of chronic lymphocytic leukaemia
(CLL), AML and MM. This niche acts as a sanctuary for the cancerous cells, protecting them from
chemotherapeutics and encouraging clonal cell survival. It does this by upregulating a plethora of
signalling cascades within the malignant cell, with the phosphatidylinositol-3-kinase (PI3K) pathway
taking a critical role. This review will focus on how the PI3K pathway influences disease progression
and the individualised role of the PI3K subunits. We will also summarise the current clinical trials for
PI3K inhibitors and how these trials impact the treatment of blood cancers.
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1. Introduction
The phosphatidylinositol-3-kinase (PI3K) pathway has been shown to be constitutively active
in the majority of multiple myeloma (MM) and acute myeloid leukaemia (AML) cells [1–3] and is
critical for the tumour cell growth and survival [4–6]. This activation can be attributed to both the
cytokines within the bone marrow microenvironment (BMM) and the adhesion of malignant cells to
the extracellular matrix [7–9]. Moreover, disruption of the PI3K pathway has been shown to cause cell
cycle arrest and apoptosis in an assortment of cancers [10–12]. Many reviews have highlighted the
importance of PI3K in chronic lymphocytic leukaemia (CLL), therefore, this review aims to describe
the known individualised roles of the p110 PI3K regulatory subunits (alpha, beta, gamma and delta)
in the context of MM and AML. In addition, we will discuss the potential for using PI3K-targeted
inhibitors in clinical trials to treat these diseases.
Both MM and AML are haematological malignancies with poor prognoses. Combined,
these diseases account for approximately 50,000 deaths per year in the USA [13]. With both AML
and MM primarily being diseases of the elderly (average age of diagnosis approx. 67 and 69 years
respectively [14]), these malignancies are set to become an ever-increasing problem as life expectancy
continues to rise. MM is a cancer of the plasma cell, the terminal differentiation stage of a B-cell, and is
characterised by the accumulation of these monoclonal cells within the bone marrow. This can cause
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the patient to develop osteolytic lesions, immunodeficiency and renal failure [15]. In contrast, AML
comprises a group of biologically varied disorders of the haematopoietic myeloid progenitor cells
which rapidly results in bone marrow failure.
Despite their physiological differences, both of these malignancies at diagnosis are characterised
by the expansion of tumorous cells predominantly within the bone marrow. The presence of tumour
cells in the peripheral blood is a poor prognostic factor of both diseases and has been linked to a more
aggressive or established malignancy [16,17]. Within the bone marrow, malignant cells have been
shown to be protected from chemotherapy and encouraged to proliferate, grow and migrate [18–21].
Indeed, removal of the cells from this environment into culture results in rapid apoptosis, emphasising
the symbiotic relationship between the cancer and the niche in which it proliferates [22,23]. For many
patients, current chemotherapies fail to clear the bone marrow of visible disease. Furthermore,
even in patients who appear to initially respond well to treatment, a sub-population of cancerous cells
defined as minimal residual disease (MRD) may persist and are a primary cause of relapse in this
group [24–27]. In the past 20 years, the development of novel treatments has improved MM/AML
patient outcome significantly but despite this progress, resistant or relapsed disease remains inevitable
for most. The focus of research is now shifting from the malignancy itself to the beneficial stimuli of
the environment in which it resides, with the aim of improving therapies with reduced toxicities and
ultimately reducing MRD and increasing time between relapse.
2. Phosphatidylinositol 3-Kinase (PI3K) Activation in Cancer
PI3Ks are known to aid the regulation of many differing cell functions, including survival and
proliferation. The incongruous activation of the PI3K pathway is common to many cancers, and is
well described in MM and AML. When activated, PI3K is able to phosphorylate PIP2, a phospholipid
component of the cell membrane, to become PIP3 (Figure 1). PIP3 acts as a docking site for proteins with
pleckstrin-homology (PH) domains, which includes the master kinase Phosphoinositide-dependent
kinase 1 (PDK1) and its downstream target AKT (also known as protein kinase B). AKT can then activate
a plethora of pro-survival signalling cascades, resulting in a reduction in apoptosis and increase in cell
motility, survival and growth. Under typical conditions, the lipid phosphatase PTEN (phosphatase
and tensin homolog) acts as a negative regulator of the PI3K pathway, de-phosphorylating PIP3 and
preventing AKT activation-effectively “turning off” the PI3K pathway. Loss of PTEN functionality has
been reported in several cancer types, further enhancing the pro-tumoural effect of the PI3K pathway
and correlating with a more aggressive disease phenotype.
There are three classes of PI3Ks, with class I being most frequently linked with cancer development.
This class of PI3Ks consists of a regulatory subunit and one of four catalytic subunits: p110α, p110β, and
p110δ (Class 1A) and p110γ (Class 1B). Whilst a relatively low percentage of PI3K or PTEN mutations
are observed in both MM and AML cells [28,29], all four of these isoforms have been shown to be
overexpressed in cell lines and primary tissue. p110α and p110β subunits are expressed ubiquitously
in cells. Furthermore, p110δ and p110γ are known to be specifically enriched by the haematopoietic
system—primarily in leukocytes [30]. This is of interest when considering haematological malignancies
as it potentially provides a more tissue-specific, localised target for the treatment of white blood cell
malignancies with fewer side effects for patients. Below, we have separated the individual PI3K
subunits into sections in order to discuss suitability as a target in blood cancers.
2.1. p110α
p110α has long been associated with many different cancers, including cervical [31] and breast
cancer [32]. Increased copy number of the PIK3CA gene and subsequent 3q26.3 amplification was
found in a significant percentage of primary tissues in these studies, however this is the only
PI3K subunit for which a somatic activation has so far been identified [33,34]. This mutation
can often be found in concordance with a loss of PTEN functionality—most commonly in breast,
endometrial and colon cancers [35]—further increasing the role of the PI3K pathway in tumorigenesis.
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Despite this mutation being so frequent in solid tumours, it is uncommon in plasma cell disorders
and haematological malignancies in general and is only seen at the most advanced stages of plasma
cell leukaemia [36]. Recently, it has been shown that inhibition of p110α on its own may not be
effective in Luminal Breast Cancer, due to a compensatory rapid accumulation of PIP3 produced by
the p110β isoform [37]. This activation, however, did not consistently restore AKT phosphorylation,
raising questions about the reliability of phospho-AKT monitored PI3K activation.
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phosphorylated via receptor tyrosine kinases (RTKs) and G-protein coupled receptors (GCPRs) located
in the cell surfac membrane. This causes activation of AKT and its dow stream targets, resulting in
increased cell survival and migration.
2.2. p110β
p110β s li e to platelet a gregation [38] and is unique in that it has been shown to
be activated by both receptor tyrosine kinases (RTK) and G-protein coupled receptors (GCPR) [39].
Mutations in the PIK3CB gene are rare, however increased expression of this gene has been observed in
prostate cancer [40], with knockdown (KD) of this gene resulting in increased apoptosis and cell cycle
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arrest in stage G1. p110β has been shown to be required to maintain PI3K signalling in PTEN-deficient
cancer cells, indicating the opportunity for isoform-specific inhibition in the treatment of this cancer
type [41]. In MM, the necessity for p110β is not yet established—with knockdown (KD) of this gene so
far reported as proving to be insignificant in terms of cell survival [42]. AML cells however have been
shown to become sensitised to chemotherapeutics upon p110β KD, with significant reduction in cell
viability [43].
2.3. p110δ
Alongside p110γ, p110δ plays a critical role in haematological malignancy pathogenesis and in
addition has been linked to various immune disorders, such as PI3Kδ syndrome and inflammatory
bowel disease [44,45]. p110δ has a critical role in B-Cell development and has been shown to have an
oncogenic role in a number of blood cancers, including CLL, acute lymphoblastic leukaemia (ALL),
MM and AML [6,46,47]. This has led to the development of p110δ-specific inhibitors, discussed below,
that have been shown to slow and reduce tumour growth, even in the presence of protective bone
marrow microenvironment (BMM) signalling.
2.4. p110γ
p110γ has been shown to have a critical role in GCPR-mediated PIP3 production, which in turn
strictly controls cell motility in macrophages [48]. Mutation of the PI3KCG gene has previously been
implicated in lung cancer [49] and inhibition of the p110γ subunit resulted in reduced proliferation
of these cells in idiopathic pulmonary fibrosis [50]. Considering this isoform’s prominent role in
macrophage motility, this may provide a therapeutic target in AML.
3. PI3K Pathway Activation
The PI3K pathway has been shown to be activated via a wide assortment of receptor tyrosine
kinases (RTKs)—including platelet-derived growth factor receptor (PDGFR) [51,52], c-MET [53],
insulin-like growth factor-I receptor (IGF-IR) [54] and Fms-Related Tyrosine Kinase 3 (FLT3) [55].
Constitutive activation of these RTKs (either by mutation/duplication of the RTK such as that reported
in AML [56] or overexpression of its complimentary ligand) results in the upregulation of this pathway
and has been associated with poor patient prognosis in many cancer types [57,58]. As previously
mentioned, G-coupled protein receptors have also been linked to PI3K activation, however this
is specific to the p110δ/γ subunits and is not yet well defined. Micro-environmental factors that
have been shown to directly contribute to both MM and AML pathogenesis (Table 1) have also
been associated with PI3K pathway upregulation, inferring the presence of a positive feedback loop.
Of these, Interleukin-6 (IL-6) and Stromal-Derived Factor-1 (SDF-1) are arguably the most significant
in MM and AML pathogenesis and have been shown to be stimulated by tumour cell/BMM cell
interactions. This special relationship is discussed in more detail below.
4. The Protective Effect of the Bone Marrow Microenvironment
The bone marrow microenvironment comprises a plethora of cell types, including macrophages,
fibroblastic stromal cells and endothelial cells [59]. In addition to these cells, there is also a vast set
of growth factors, cytokines and hormones that contribute to the complex haematopoietic process.
The physiologic balance of these soluble factors is influenced by the presence of malignant cells in both
AML and MM which results in biological changes within the stromal cells (as well as the malignant cells
themselves) to benefit disease progression [60]. This pro-tumoural environment promotes activation
of signalling cascades within both benign and malignant cells which inhibit apoptosis, and promote
processes such as proliferation and angiogenesis. Many of these soluble factors upregulate the PI3K
pathway, a summary of which is shown in Table 1.
IL-6, for example, is critical in MM disease progression, with IL-6 deficient mice unable to develop
MM [61] and elevated IL-6 serum levels being associated with poor patient prognosis [62]. In AML,
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in addition to PI3K pathway activation, IL-6 has been shown to activate the Jak/Stat pathway via
Stat3 [63]—a pathway that is known to be commonly dis-regulated in a sub-set of AML patients [64].
Therapies that abrogate IL-6 triggered cascades (such as monoclonal antibody therapy [65]) have been
shown to help overcome chemotherapy resistant sub-populations of malignant cells. These agents
have also achieved remarkable efficacy in clinical trials in both relapsed/refractory MM [66] and
AML [67]. Malignant cells are also known to be protected in the BMM when adhered to the extracellular
matrix [68–71] (collagen, fibronectin and laminin) or to bone marrow mesenchymal stromal cells
(BM-MSCs) [72]. Interestingly, our group has shown that activation of BM-MSC by AML co-culture
is not inhibited by the pan-PI3K inhibitor LY294002 [73], thus suggesting that PI3K inhibition in
the context of the malignant BMM will not have adverse effects on the surrounding environment.
However, these results are from in vitro co-cultures and the translation to in vivo models needs to be
further investigated.
Stromal-derived factor 1 (SDF-1), also known as CXCL12, is present in the BMM in high
concentrations. It is produced by stromal cells and is a chemo-attractant to both AML and MM cells,
causing them to ‘home’ to the bone marrow [74,75]. As well as mediating cell migration, SDF-1 has been
shown to promote haematopoiesis, increasing the proliferation rates of CD34+ cells [76]. Upon binding,
MM cells have been shown to undergo growth arrest [77] as well as the upregulation of pro-survival
pathways and secretion of cytokines that are beneficial to both the cancerous cells and the environment
on which they depend. AML cells too are known to depend on this adhesion, becoming sensitised to
chemotherapeutics upon antagonising CXCR4 [78].
In vitro 3D tissue culture techniques provide a potential improvement to traditional 2D cultures
as they can provide a scaffold on which to grow extracellular components and can be utilised to
study the effect of malignant cells in an environment similar to the BM [79]. These technologies
offer an alternative to 2D cultures but do not mimic the biological system of the murine models
that are currently used to understand the microenvironment in the pathogenesis of MM and AML.
The complex nature of the BMM and its interactions with haematological malignancies is an area
under intense investigation as we and others believe that targeting the environment could well be
a means of eradicating the tumour. There are currently two types of animal models routinely used
in the study of blood cancers: (1) injection of malignant cells into immune deficient mice (such as
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice); and (2) the injection of allogenic malignant cells into
C57BL/6 mice. A third model has recently been proposed in which a scaffold is implanted into immune
deficient mice that comprises the patient’s microenvironment and the malignant cell [80]. There are,
however, several limitations of these models when considering the BMM. In the immune deficient
mice, the absence of a functional immune system and its interactions with the human malignancy is
not representative of a natural tumour environment. Subsequently, compounds that may have shown
promise in a pre-clinical setting do not translate well into clinical trials [81].
When looking at allogenic tumour models, it is pertinent to understand that species–species
differences do occur. For example, telomerase (which is for the most part inactive in adult human cells)
is still active in a murine model, suggesting that murine cells are more likely to undergo malignant
transformation [82]. In addition, the gene that codes for the cytokine IL-8 (which is critical for MM
disease progression and osteoclastic differentiation [83]) is not present in the murine genome [84]).
New models are always in development, and recent work has been done to ‘humanise’ the mouse
bone marrow, with the aim of replicating the natural microenvironment [85]. Briefly, BM-MSCs can be
used to reform the bone marrow of a radiation depleted NSG mouse on which a patient’s malignant
cells are transplanted resulting in ‘XactMice’ or ‘xenochimeric’ mice. This step of essentially providing
the mice with a bone marrow transplant should make the model a more accurate reflection of a human
immune system.
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Table 1. Common cytokines and soluble factors involved in the pathogenesis of haemic malignancies
that are also implicated in PI3K/Akt pathway activation.
Soluble
Factor Involvement in MM Pathogenesis
Involvement in AML
Pathogenesis
Involvement in
PI3K/Akt Pathway
APRIL Survival factor for BM plasmablasts [86] [87]
BAFF Normal plasma cell development [88] [87,89]
IGF-1 Induces growth in all MM cell lines,promotes cell cycle progression [90,91] [92]
IL-6 Promotes drug resistance, high levelsassociated with poor prognosis [93,94]
Upregulates STAT3 increasing
AML proliferation and
survival [63]
[95,96]
IL-8 Increases osteoclastogenesis and promotesangiogenesis [97]
Increases survival, invasion and
proliferation of AML cells [98] [99]
MIP-1a Increased survival and osteoclastproduction [100] [101]
SDF-1 Mediates MM homing to the BM; tumourgrowth; drug resistance [74]
Mediates AML migration, BTK
shown to be involved [102,103] [104]
TNFα Induces expression of pro-survivalfactors [105]
Stimulates AML blast growth
via colony stimulating
factor [106]
[107]
VEGF Angiogenesis, promotes MM survival andattenuates apoptosis [108]
Upregulated, increases rate of
angiogenesis [109,110] [111]
5. Clinical Implications
Scientific observations on PI3K signalling in cancer have resulted in the development of a
number of PI3K pathway inhibitors over the past 15 years, including isoform-specific inhibitors,
which are now in clinical trials across a spectrum of haematological malignancies (a selection of
recent trials is highlighted in Table 2). The first wave of PI3K pathway inhibitors to reach the clinic
were rapalogues (rapamycin and its analogues) which work via inhibiting mTOR, a downstream
target of PI3K activation. Although these drugs were effective in several forms of neoplasms
(including neuroendocrine tumours [112] and mantle-cell lymphoma [113]), their use as a single
agent treatment was limited due to compensatory pathway activation and subsequent resistance.
Rapalogue development was closely followed by the use of small molecules that bound to the catalytic
site of mTOR [114] and dual pan-class I PI3K/mTOR inhibitors. These second-generation compounds
provided an advantage as they could target the PI3K pathway at two points, suppressing both
mTORC1/C2 and PI3K itself [115].
The PI3K/Akt pathway has previously been implicated in the stabilisation of Hypoxia inducible
factor 1α (HIF-1α) which is a key regulator in metabolic adaption to low oxygen [116]. This is
achieved via the activation of heat shock proteins (Hsp) including Hsp90 and Hsp70, which are
known to act in conjunction as molecular chaperones, and have been shown to be over-expressed
in many human cancers [117–119]. The acute role of Hsps has been described in both AML and
MM, where they have been shown to be critical for malignant cell growth and survival [120,121].
Interestingly, AML blasts with a FMS-like tyrosine kinase 3 (FLT-3) mutation are highly sensitive to
the Hsp90 inhibitor Ganetespib [122,123]. Inhibiting the PI3K pathway therefore has the potential to
reduce the activity of Hsps, especially in the sub-population of patients with FLT3 mutations.
Pan-PI3K inhibition, although effective, can have dose-limiting and adverse effects including
hyperglycaemia and varying gastrointestinal conditions. When used in the treatment of breast
cancer, clinical studies showed that approximately 60% of patients experienced stomatitis with
immunosuppression and non-infectious pneumonitis also presenting at high frequency (40% and 15%
respectively) [124]. The inhibition of the specific PI3K subunits therefore provides a far more attractive
and directed option, especially when considering elderly patients. Isoform-specific inhibition would
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be more easily tolerated in combination with traditional chemotherapeutics and could be tailored
to the individual nature of the disease. As previously mentioned, p110α and p110β are expressed
ubiquitously in many different tissue types, however, p110δ and p110γ are mainly expressed in
haematopoietic cells. Targeting just the p110δ and p110γ isoforms could therefore be beneficial for
the treatment of haematological malignancies. Consequently, several isoform-specific PI3K inhibitors
have now completed phase III trials for haematological malignancies and have started appearing in
clinics worldwide. Idelalisib (p110δ inhibitor), for example, is currently being used in combination
with rituximab for the treatment of follicular lymphoma [125], and was previously used for treating
CLL [126]. In respect to MM and AML, it would be of great benefit to use these isoform-specific PI3K
inhibitors to aid in severing the protective effects these malignant cells experience in the bone marrow.
The full potential of PI3K inhibitors as a complementary therapy has not yet been realised.
One interesting combination is the use of PI3K inhibitors in conjunction with programmed cell
death protein 1 (PD-1) inhibitors. PD-1 is expressed on activated T-lymphocytes and B cells [127],
and inhibition of this receptor effectively results in the immune system ‘attacking’ malignant cells [128].
However, PD-1 inhibition has been shown to decrease the activity of the PI3K suppressor PTEN,
subsequently causing an increase in PI3K pathway activity [129]. PI3K inhibitors could therefore
provide relief for this off-target effect and increase the efficacy of PD-1 inhibitors. Despite the plethora
of clinical trials involving PD-1 inhibition, there is currently only one phase I clinical trial looking
at the combination of PD-1 inhibitor and PI3K inhibitor and this is in solid tumours (NCT02646748).
It would be of great interest to see how this inhibition translates into haematological malignancies.
There are, however, drawbacks when considering the PI3K pathway as a therapeutic target.
For example, the PI3K pathway has significant overlap with parallel cascades and pharmacological
inhibition may result in the activation of these compensatory pathways. These include processes
such as NOTCH-MYC amplification [130] or ERK pathway activation [131], reducing the efficacy of
treatment. The biomarkers that predict both susceptibility and resistance to PI3K pathway inhibition
will also need to be identified, which when considering cancers with multiple sub-populations is
highly complex. Also, the current range of PI3K inhibitors lack sensitivity to mutant isoforms and
the therapeutic opportunities may therefore be limited. In respect to MM and AML, it would be of
great benefit to use these isoform-specific PI3K inhibitors to aid in disrupting the protective effects
that these malignant cells experience in the bone marrow. This should increase the efficacy of current
chemotherapies and increase the duration of patient remission.
Table 2. Recent PI3K pathway inhibitors in clinical trials for the treatment of common blood cancers.
Data taken from ClinicalTrials.gov.
Phase Status Drug Name Target Mono/CoTherapy
ClinicalTrials.Gov.
Number
I Completed Idelalisib p110δ Mono NCT01555281
I Recruiting CUDC-907 p110α + HDAC1/2/3/10 Mono NCT01742988
I/II Completed Afuresertib Akt Co NCT01476137
I/II Recruiting Nelfinavir pan PI3K Co NCT01555281
I/II Recruiting ACP-319 p110δ Co NCT02328014
Ib/II Completed BYL719 p110α Co NCT02144038
II Recruiting Gedatolisib p110α/γ + mTOR Mono NCT02438761
III Ongoing, not recruiting Duvelisib p110δ/γ Co NCT02004522
6. Conclusions
The PI3K pathway is a major player in terms of cancer development, however the potential
individualised roles of its catalytic subunits are yet to be fully defined, with only a small fraction of
clinical trials focussing on the PI3K isoforms. The central role of PI3K signalling in many cell types,
not just in tumorous tissue, highlights the need for specific subunit inhibition, with the expectation that
such a strategy would limit off-target effects and increase the tolerated dosages in vivo. The majority of
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key cytokines involved in AML and MM pathogenesis have been shown to activate the PI3K pathway
within the bone marrow microenvironment, accounting for the aberrant activation observed in patient
samples where no somatic mutations are present. As PI3K isoform-specific inhibitors enter clinical
trials, it remains to be seen the optimal co-therapies with which these drugs are best administered.
Finally, as p110δ/γ are primarily expressed by leukocytes and the inhibitors of these subunits (such as
those recently investigated in CLL and lymphoma [132]) have the potential to reverse some of the
protective effects of the BMM, it appears that isoform-specific inhibition of p110δ and/or γ hold the
most promise in haemic malignancies.
Acknowledgments: Rachel E. Piddock is funded by a Ph.D. studentship from the Norwich Research Park DTP
(BBSRC). In addition, we would like to thank Yvette Wormstone for proof reading the manuscript.
Conflicts of Interest: Stuart A. Rushworth has research funding from Verastem. All other authors declare no
conflict of interest.
References
1. Maiso, P.; Liu, Y.; Morgan, B.; Azab, A.K.; Ren, P.; Martin, M.B.; Zhang, Y.; Liu, Y.; Sacco, A.; Ngo, H.; et al.
Defining the role of TORC1/2 in multiple myeloma. Blood 2011, 118, 6860–6870. [CrossRef] [PubMed]
2. Lindblad, O.; Cordero, E.; Puissant, A.; Macaulay, L.; Ramos, A.; Kabir, N.N.; Sun, J.; Vallon-Christersson, J.;
Haraldsson, K.; Hemann, M.T.; et al. Aberrant activation of the PI3K/mTOR pathway promotes resistance
to sorafenib in AML. Oncogene 2016, 35, 5119–5131. [CrossRef] [PubMed]
3. Pillinger, G.; Loughran, N.V.; Piddock, R.E.; Shafat, M.S.; Zaitseva, L.; Abdul-Aziz, A.; Lawes, M.J.;
Bowles, K.M.; Rushworth, S.A. Targeting PI3Kδ and PI3Kγ signalling disrupts human AML survival
and bone marrow stromal cell mediated protection. Oncotarget 2016, 7, 39784–39795. [PubMed]
4. Ikeda, H.; Hideshima, T.; Fulciniti, M.; Perrone, G.; Miura, N.; Yasui, H.; Okawa, Y.; Kiziltepe, T.; Santo, L.;
Vallet, S.; et al. PI3K/p110δ is a novel therapeutic target in multiple myeloma. Blood 2010, 116, 1460–1468.
[CrossRef] [PubMed]
5. Billottet, C.; Grandage, V.L.; Gale, R.E.; Quattropani, A.; Rommel, C.; Vanhaesebroeck, B.; Khwaja, A.
A selective inhibitor of the p110[delta] isoform of PI 3-kinase inhibits AML cell proliferation and survival
and increases the cytotoxic effects of VP16. Oncogene 2006, 25, 6648–6659. [CrossRef] [PubMed]
6. Lannutti, B.J.; Meadows, S.A.; Herman, S.E.M.; Kashishian, A.; Steiner, B.; Johnson, A.J.; Byrd, J.C.; Tyner, J.W.;
Loriaux, M.M.; Deininger, M.; et al. CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for
the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011, 117, 591–594.
[CrossRef] [PubMed]
7. Edelmann, J.; Klein-Hitpass, L.; Carpinteiro, A.; Führer, A.; Sellmann, L.; Stilgenbauer, S.; Dührsen, U.;
Dürig, J. Bone marrow fibroblasts induce expression of PI3K/NF-κB pathway genes and a pro-angiogenic
phenotype in CLL cells. Leuk. Res. 2008, 32, 1565–1572. [CrossRef] [PubMed]
8. Dong, G.; Chen, Z.; Li, Z.-Y.; Yeh, N.T.; Bancroft, C.C.; Van Waes, C. Hepatocyte Growth Factor/Scatter
Factor-induced Activation of MEK and PI3K Signal Pathways Contributes to Expression of Proangiogenic
Cytokines Interleukin-8 and Vascular Endothelial Growth Factor in Head and Neck Squamous Cell
Carcinoma. Cancer Res. 2001, 61, 5911–5918. [PubMed]
9. Yang, L.; Wang, L.; Lin, H.-K.; Kan, P.-Y.; Xie, S.; Tsai, M.-Y.; Wang, P.-H.; Chen, Y.-T.; Chang, C. Interleukin-6
differentially regulates androgen receptor transactivation via PI3K-Akt, STAT3, and MAPK, three distinct
signal pathways in prostate cancer cells. Biochem. Biophys. Res. Commun. 2003, 305, 462–469. [CrossRef]
10. Roy, S.K.; Srivastava, R.K.; Shankar, S. Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation
of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer. J. Mol. Signal.
2010. [CrossRef] [PubMed]
11. Prasad, G.; Sottero, T.; Yang, X.; Mueller, S.; James, C.D.; Weiss, W.A.; Polley, M.-Y.; Ozawa, T.; Berger, M.S.;
Aftab, D.T.; et al. Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination
therapy with temozolomide. Neuro-Oncology 2011, 13, 384–392. [CrossRef] [PubMed]
12. Wallin, J.J.; Edgar, K.A.; Guan, J.; Berry, M.; Prior, W.W.; Lee, L.; Lesnick, J.D.; Lewis, C.; Nonomiya, J.;
Pang, J.; et al. GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer
Models Driven by the PI3K Pathway. Mol. Cancer Ther. 2011, 10, 2426–2436. [CrossRef] [PubMed]
Cancers 2017, 9, 29 9 of 15
13. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2015. CA Cancer J. Clin. 2015, 65, 5–29. [CrossRef]
[PubMed]
14. Ryerson, A.B.; Eheman, C.R.; Altekruse, S.F.; Ward, J.W.; Jemal, A.; Sherman, R.L.; Henley, S.J.; Holtzman, D.;
Lake, A.; Noone, A.M. Annual Report to the Nation on the Status of Cancer, 1975–2012, featuring the
increasing incidence of liver cancer. Cancer 2016, 122, 1312–1337. [CrossRef] [PubMed]
15. Palumbo, A.; Anderson, K. Multiple Myeloma. N. Engl. J. Med. 2011, 364, 1046–1060. [CrossRef] [PubMed]
16. Bianchi, G.; Kyle, R.A.; Larson, D.R.; Witzig, T.E.; Kumar, S.; Dispenzieri, A.; Morice, W.G.; Rajkumar, S.V.
High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering
multiple myeloma. Leukemia 2013, 27, 680–685. [CrossRef] [PubMed]
17. Feller, N.; Schuurhuis, G.J.; van der Pol, M.A.; Westra, G.; Weijers, G.W.D.; van Stijn, A.; Huijgens, P.C.;
Ossenkoppele, G.J. High percentage of CD34-positive cells in autologous AML peripheral blood stem cell
products reflects inadequate in vivo purging and low chemotherapeutic toxicity in a subgroup of patients
with poor clinical outcome. Leukemia 2003, 17, 68–75. [CrossRef] [PubMed]
18. Meads, M.B.; Hazlehurst, L.A.; Dalton, W.S. The Bone Marrow Microenvironment as a Tumor Sanctuary and
Contributor to Drug Resistance. Clin. Cancer Res. 2008, 14, 2519–2526. [CrossRef] [PubMed]
19. Murray, M.Y.; Rushworth, S.A.; Zaitseva, L.; Bowles, K.M.; Macewan, D.J. Attenuation of
dexamethasone-induced cell death in multiple myeloma is mediated by miR-125b expression. Cell Cycle
2013, 12, 2144–2153. [CrossRef] [PubMed]
20. Shah, N.M.; Rushworth, S.A.; Murray, M.Y.; Bowles, K.M.; MacEwan, D.J. Understanding the role of
NRF2-regulated miRNAs in human malignancies. Oncotarget 2013, 4, 1130–1142. [CrossRef] [PubMed]
21. Shafat, M.S.; Oellerich, T.; Mohr, S.; Robinson, S.D.; Edwards, D.R.; Marlein, C.R.; Piddock, R.E.; Fenech, M.;
Zaitseva, L.; Abdul-Aziz, A.; et al. Leukemic blasts program bone marrow adipocytes to generate a
protumoral microenvironment. Blood 2017, 129, 1320–1332. [CrossRef] [PubMed]
22. Zlei, M.; Egert, S.; Wider, D.; Ihorst, G.; Wäsch, R.; Engelhardt, M. Characterization of in vitro growth of
multiple myeloma cells. Exp. Hematol. 2007, 35, 1550–1561. [CrossRef] [PubMed]
23. Ito, S.; Barrett, A.J.; Dutra, A.; Pak, E.; Miner, S.; Keyvanfar, K.; Hensel, N.F.; Rezvani, K.; Muranski, P.;
Liu, P.; et al. Long term maintenance of myeloid leukemic stem cells cultured with unrelated human
mesenchymal stromal cells. Stem Cell Res. 2015, 14, 95–104. [CrossRef] [PubMed]
24. Eckert, C.; Biondi, A.; Seeger, K.; Cazzaniga, G.; Hartmann, R.; Beyermann, B.; Pogodda, M.; Proba, J.;
Henze, G. Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia.
Lancet 2001, 358, 1239–1241. [CrossRef]
25. San Miguel, J.F.; Martínez, A.; Macedo, A.; Vidriales, M.B.; López-Berges, C.; González, M.; Caballero, D.;
García-Marcos, M.A.; Ramos, F.; Fernández-Calvo, J.; et al. Immunophenotyping Investigation of Minimal
Residual Disease Is a Useful Approach for Predicting Relapse in Acute Myeloid Leukemia Patients. Blood
1997, 90, 2465–2470. [PubMed]
26. Cavo, M.; Terragna, C.; Martinelli, G.; Ronconi, S.; Zamagni, E.; Tosi, P.; Lemoli, R.M.; Benni, M.; Pagliani, G.;
Bandini, G.; et al. Molecular monitoring of minimal residual disease in patients in long-term complete
remission after allogeneic stem cell transplantation for multiple myeloma. Blood 2000, 96, 355–357. [PubMed]
27. Murray, M.Y.; Zaitseva, L.; Auger, M.J.; Craig, J.I.; MacEwan, D.J.; Rushworth, S.A.; Bowles, K.M. Ibrutinib
inhibits BTK-driven NF-kappaB p65 activity to overcome bortezomib-resistance in multiple myeloma.
Cell Cycle 2015, 14, 2367–2375. [CrossRef] [PubMed]
28. Chapman, M.A.; Lawrence, M.S.; Keats, J.J.; Cibulskis, K.; Sougnez, C.; Schinzel, A.C.; Harview, C.L.;
Brunet, J.-P.; Ahmann, G.J.; Adli, M.; et al. Initial genome sequencing and analysis of multiple myeloma.
Nature 2011, 471, 467–472. [CrossRef] [PubMed]
29. Ding, L.; Ley, T.J.; Larson, D.E.; Miller, C.A.; Koboldt, D.C.; Welch, J.S.; Ritchey, J.K.; Young, M.A.;
Lamprecht, T.; McLellan, M.D.; et al. Clonal evolution in relapsed acute myeloid leukaemia revealed
by whole-genome sequencing. Nature 2012, 481, 506–510. [CrossRef] [PubMed]
30. Koyasu, S. The role of PI3K in immune cells. Nat. Immunol. 2003, 4, 313–319. [CrossRef] [PubMed]
31. Ma, Y.-Y.; Wei, S.-J.; Lin, Y.-C.; Lung, J.-C.; Chang, T.-C.; Whang-Peng, J.; Liu, J.M.; Yang, D.-M.; Yang, W.K.;
Shen, C.-Y. PIK3CA as an oncogene in cervical cancer. Oncogene 2000, 19, 2739–2744. [CrossRef] [PubMed]
32. Bachman, K.E.; PArgani; Samuels, Y.; Silliman, N.; Ptak, J.; Szabo, S.; Konishi, H.; Karakas, B.; Blair, B.G.;
Lin, C.; et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol. Ther.
2004, 3, 772–775. [CrossRef] [PubMed]
Cancers 2017, 9, 29 10 of 15
33. Wu, G.; Xing, M.; Mambo, E.; Huang, X.; Liu, J.; Guo, Z.; Chatterjee, A.; Goldenberg, D.; Gollin, S.M.;
Sukumar, S. Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res.
2005, 7, R609–R616. [CrossRef] [PubMed]
34. Levine, D.A.; Bogomolniy, F.; Yee, C.J.; Lash, A.; Barakat, R.R.; Borgen, P.I.; Boyd, J. Frequent mutation of the
PIK3CA gene in ovarian and breast cancers. Clin. Cancer Res. 2005, 11, 2875–2878. [CrossRef] [PubMed]
35. Yuan, T.L.; Cantley, L.C. PI3K pathway alterations in cancer: Variations on a theme. Oncogene 2008, 27,
5497–5510. [CrossRef] [PubMed]
36. Tiedemann, R.; Gonzalez-Paz, N.; Kyle, R.; Santana-Davila, R.; Price-Troska, T.; van Wier, S.; Chng, W.;
Ketterling, R.P.; Gertz, M.; Henderson, K. Genetic aberrations and survival in plasma cell leukemia. Leukemia
2008, 22, 1044–1052. [CrossRef] [PubMed]
37. Costa, C.; Ebi, H.; Martini, M.; Beausoleil, S.A.; Faber, A.C.; Jakubik, C.T.; Huang, A.; Wang, Y.; Nishtala, M.;
Hall, B.; et al. Measurement of PIP3 Levels Reveals an Unexpected Role for p110β in Early Adaptive
Responses to p110α-Specific Inhibitors in Luminal Breast Cancer. Cancer Cell 2015, 27, 97–108. [CrossRef]
[PubMed]
38. Jackson, S.P.; Schoenwaelder, S.M.; Goncalves, I.; Nesbitt, W.S.; Yap, C.L.; Wright, C.E.; Kenche, V.;
Anderson, K.E.; Dopheide, S.M.; Yuan, Y.; et al. PI 3-kinase p110beta: A new target for antithrombotic
therapy3-kinase p110beta: A new target for antithrombotic therapy. Nat. Med. 2005, 11, 507–514. [CrossRef]
[PubMed]
39. Guillermet-Guibert, J.; Bjorklof, K.; Salpekar, A.; Gonella, C.; Ramadani, F.; Bilancio, A.; Meek, S.;
Smith, A.J.H.; Okkenhaug, K.; Vanhaesebroeck, B. The p110β isoform of phosphoinositide 3-kinase signals
downstream of G protein-coupled receptors and is functionally redundant with p110γ. Proc. Natl. Acad.
Sci. USA 2008, 105, 8292–8297. [CrossRef] [PubMed]
40. Zhu, Q.; Youn, H.; Tang, J.; Tawfik, O.; Dennis, K.; Terranova, P.F.; Du, J.; Raynal, P.; Thrasher, J.B.; Li, B.
Phosphoinositide 3-OH kinase p85α and p110β are essential for androgen receptor transactivation and
tumor progression in prostate cancers. Oncogene 2008, 27, 4569–4579. [CrossRef] [PubMed]
41. Wee, S.; Wiederschain, D.; Maira, S.-M.; Loo, A.; Miller, C.; deBeaumont, R.; Stegmeier, F.; Yao, Y.-M.;
Lengauer, C. PTEN-deficient cancers depend on PIK3CB. Proc. Natl. Acad. Sci. USA 2008, 105, 13057–13062.
[CrossRef] [PubMed]
42. Hofmann, C.; Stühmer, T.; Schmiedl, N.; Wetzker, R.; Mottok, A.; Rosenwald, A.; Langer, C.; Zovko, J.;
Chatterjee, M.; Einsele, H. PI3K-dependent multiple myeloma cell survival is mediated by the PIK3CA
isoform. Br. J. Haematol. 2014, 166, 529–539. [CrossRef] [PubMed]
43. Doepfner, K.T.; Spertini, O.; Arcaro, A. Autocrine insulin-like growth factor-I signaling promotes growth and
survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase//Akt pathway. Leukemia
2007, 21, 1921–1930. [CrossRef] [PubMed]
44. Okkenhaug, K.; Bilancio, A.; Farjot, G.; Priddle, H.; Sancho, S.; Peskett, E.; Pearce, W.; Meek, S.E.; Salpekar, A.;
Waterfield, M.D.; et al. Impaired B and T Cell Antigen Receptor Signaling in p110δ PI 3-Kinase Mutant Mice.
Science 2002, 297, 1031–1034. [PubMed]
45. Lucas, C.L.; Kuehn, H.S.; Zhao, F.; Niemela, J.E.; Deenick, E.K.; Palendira, U.; Avery, D.T.; Moens, L.;
Cannons, J.L.; Biancalana, M.; et al. Dominant-activating germline mutations in the gene encoding the PI(3)K
catalytic subunit p110[delta] result in T cell senescence and human immunodeficiency. Nat. Immunol. 2014,
15, 88–97. [CrossRef] [PubMed]
46. Sujobert, P.; Bardet, V.; Cornillet-Lefebvre, P.; Hayflick, J.S.; Prie, N.; Verdier, F.; Vanhaesebroeck, B.; Muller, O.;
Pesce, F.; Ifrah, N.; et al. Essential role for the p110δ isoform in phosphoinositide 3-kinase activation and cell
proliferation in acute myeloid leukemia. Blood 2005, 106, 1063–1066. [CrossRef] [PubMed]
47. Piddock, R.E.; Loughran, N.; Marlein, C.R.; Robinson, S.D.; Edwards, D.R.; Yu, S.; Pillinger, G.E.; Zhou, Z.;
Zaitseva, L.; Auger, M.J.; et al. PI3Kdelta and PI3Kgamma isoforms have distinct functions in regulating
pro-tumoural signalling in the multiple myeloma microenvironment. Blood Cancer J. 2017, 7, e539. [CrossRef]
[PubMed]
48. Hirsch, E.; Katanaev, V.L.; Garlanda, C.; Azzolino, O.; Pirola, L.; Silengo, L.; Sozzani, S.; Mantovani, A.;
Altruda, F.; Wymann, M.P. Central Role for G Protein-Coupled Phosphoinositide 3-Kinase γ in Inflammation.
Science 2000, 287, 1049–1053. [CrossRef] [PubMed]
Cancers 2017, 9, 29 11 of 15
49. Belloni, E.; Veronesi, G.; Rotta, L.; Volorio, S.; Sardella, D.; Bernard, L.; Pece, S.; di Fiore, P.P.; Fumagalli, C.;
Barberis, M.; et al. Whole exome sequencing identifies driver mutations in asymptomatic computed
tomography-detected lung cancers with normal karyotype. Cancer Genet. 2015, 208, 152–155. [CrossRef]
[PubMed]
50. Conte, E.; Gili, E.; Fruciano, M.; Korfei, M.; Fagone, E.; Iemmolo, M.; Furno, D.L.; Giuffrida, R.; Crimi, N.;
Guenther, A.; et al. PI3K p110[gamma] overexpression in idiopathic pulmonary fibrosis lung tissue and
fibroblast cells: In vitro effects of its inhibition. Lab. Investig. 2013, 93, 566–576. [CrossRef] [PubMed]
51. Zhang, H.; Bajraszewski, N.; Wu, E.; Wang, H.; Moseman, A.P.; Dabora, S.L.; Griffin, J.D.; Kwiatkowski, D.J.
PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J. Clin. Investig. 2007, 117,
730–738. [CrossRef] [PubMed]
52. Pickett, E.A.; Olsen, G.S.; Tallquist, M.D. Disruption of PDGFRα-initiated PI3K activation and migration of
somite derivatives leads to spina bifida. Development 2008, 135, 589–598. [CrossRef] [PubMed]
53. Maulik, G.; Madhiwala, P.; Brooks, S.; Ma, P.; Kijima, T.; Tibaldi, E.; Schaefer, E.; Parmar, K.; Salgia, R.
Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung
cancer. J. Cell. Mol. Med. 2002, 6, 539–553. [CrossRef] [PubMed]
54. Torres-Arzayus, M.I.; de Mora, J.F.; Yuan, J.; Vazquez, F.; Bronson, R.; Rue, M.; Sellers, W.R.; Brown, M.
High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an
oncogene. Cancer Cell 2004, 6, 263–274. [CrossRef] [PubMed]
55. Rottapel, R.; Turck, C.W.; Casteran, N.; Liu, X.; Birnbaum, D.; Pawson, T.; Dubreuil, P. Substrate specificities
and identification of a putative binding site for PI3K in the carboxy tail of the murine Flt3 receptor tyrosine
kinase. Oncogene 1994, 9, 1755–1765. [PubMed]
56. Abu-Duhier, F.; Goodeve, A.; Wilson, G.; Gari, M.; Peake, I.; Rees, D.; Vandenberghe, E.; Winship, P.; Reilly, J.
FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group.
Br. J. Haematol. 2000, 111, 190–195. [CrossRef] [PubMed]
57. Ocana, A.; Vera-Badillo, F.; Al-Mubarak, M.; Templeton, A.J.; Corrales-Sanchez, V.; Diez-Gonzalez, L.;
Cuenca-Lopez, M.D.; Seruga, B.; Pandiella, A.; Amir, E. Activation of the PI3K/mTOR/AKT Pathway and
Survival in Solid Tumors: Systematic Review and Meta-Analysis. PLoS ONE 2014, 9, e95219. [CrossRef]
[PubMed]
58. Ying, J.; Xu, Q.; Liu, B.; Zhang, G.; Chen, L.; Pan, H. The expression of the PI3K/AKT/mTOR pathway
in gastric cancer and its role in gastric cancer prognosis. Onco Targets Ther. 2015, 8, 2427–2433. [CrossRef]
[PubMed]
59. Allen, T.D.; Dexter, T.M. The essential cells of the hemopoietic microenvironment. Exp. Hematol. 1984, 12,
517–521. [PubMed]
60. Colmone, A.; Amorim, M.; Pontier, A.L.; Wang, S.; Jablonski, E.; Sipkins, D.A. Leukemic Cells Create Bone
Marrow Niches That Disrupt the Behavior of Normal Hematopoietic Progenitor Cells. Science 2008, 322,
1861–1865. [CrossRef] [PubMed]
61. Zhang, X.; Gaillard, J.P.; Robillard, N.; Lu, Z.Y.; Gu, Z.J.; Jourdan, M.; Boiron, J.; Bataille, R.; Klein, B.
Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human
multiple myeloma. Blood 1994, 83, 3654–3663. [PubMed]
62. Nachbaur, D.M.; Herold, M.; Maneschg, A.; Huber, H. Serum levels of interleukin-6 in multiple myeloma
and other hematological disorders: Correlation with disease activity and other prognostic parameters.
Ann. Hematol. 1991, 62, 54–58. [CrossRef] [PubMed]
63. Schuringa, J.J.; Wierenga, A.T.; Kruijer, W.; Vellenga, E. Constitutive Stat3, Tyr705, and Ser727
phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6. Blood
2000, 95, 3765–3770. [PubMed]
64. Lee, H.J.; Daver, N.; Kantarjian, H.M.; Verstovsek, S.; Ravandi, F. The Role of JAK Pathway Dysregulation in
the Pathogenesis and Treatment of Acute Myeloid Leukemia. Clin. Cancer Res. 2013, 19, 327–335. [CrossRef]
[PubMed]
65. Trikha, M.; Corringham, R.; Klein, B.; Rossi, J.-F. Targeted Anti-Interleukin-6 Monoclonal Antibody Therapy
for Cancer. A Review of the Rationale and Clinical Evidence. Clin. Cancer Res. 2003, 9, 4653–4665. [PubMed]
66. Richardson, P.G.; Barlogie, B.; Berenson, J.; Singhal, S.; Jagannath, S.; Irwin, D.; Rajkumar, S.V.; Srkalovic, G.;
Alsina, M.; Alexanian, R.; et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl.
J. Med. 2003, 348, 2609–2617. [CrossRef] [PubMed]
Cancers 2017, 9, 29 12 of 15
67. Horton, T.M.; Perentesis, J.P.; Gamis, A.S.; Alonzo, T.A.; Gerbing, R.B.; Ballard, J.; Adlard, K.; Howard, D.S.;
Smith, F.O.; Jenkins, G.; et al. A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or
cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: A report
from the Children’s Oncology Group. Pediatr. Blood Cancer 2014, 61, 1754–1760. [CrossRef] [PubMed]
68. Kortlepel, K.; Bendall, L.J.; Gottlieb, D.J. Human acute myeloid leukaemia cells express adhesion proteins and
bind to bone marrow fibroblast monolayers and extracellular matrix proteins. Leukemia 1993, 7, 1174–1179.
[PubMed]
69. Landowski, T.H.; Olashaw, N.E.; Agrawal, D.; Dalton, W.S. Cell adhesion-mediated drug resistance
(CAM-DR) is associated with activation of NF-κB (RelB/p50) in myeloma cells. Oncogene 2003, 22, 2417–2421.
[CrossRef] [PubMed]
70. Hazlehurst, L.A.; Dalton, W.S. Mechanisms Associated with cell Adhesion Mediated Drug Resistance
(CAM-DR) in Hematopoietic Malignancies. Cancer Metastasis Rev. 2001, 20, 43–50. [CrossRef] [PubMed]
71. Matsunaga, T.; Takemoto, N.; Sato, T.; Takimoto, R.; Tanaka, I.; Fujimi, A.; Akiyama, T.; Kuroda, H.;
Kawano, Y.; Kobune, M. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor
for minimal residual disease of acute myelogenous leukemia. Nat. Med. 2003, 9, 1158–1165. [CrossRef]
[PubMed]
72. Corre, J.; Mahtouk, K.; Attal, M.; Gadelorge, M.; Huynh, A.; Fleury-Cappellesso, S.; Danho, C.; Laharrague, P.;
Klein, B.; Rème, T. Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia 2007,
21, 1079–1088. [CrossRef] [PubMed]
73. Abdul-Aziz, A.M.; Shafat, M.S.; Mehta, T.K.; di Palma, F.; Lawes, M.J.; Rushworth, S.A.; Bowles, K.M.
MIF-Induced Stromal PKCβ/IL8 Is Essential in Human Acute Myeloid Leukemia. Cancer Res. 2017, 77,
303–311. [CrossRef] [PubMed]
74. Alsayed, Y.; Ngo, H.; Runnels, J.; Leleu, X.; Singha, U.K.; Pitsillides, C.M.; Spencer, J.A.; Kimlinger, T.;
Ghobrial, J.M.; Jia, X.; et al. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and
homing in multiple myeloma. Blood 2007, 109, 2708–2717. [CrossRef] [PubMed]
75. Rombouts, E.J.C.; Pavic, B.; Löwenberg, B.; Ploemacher, R.E. Relation between CXCR-4 expression, Flt3
mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood 2004, 104, 550–557. [CrossRef]
[PubMed]
76. Lataillade, J.J.; Clay, D.; Dupuy, C.; Rigal, S.; Jasmin, C.; Bourin, P.; Le Bousse-Kerdiles, M.C. Chemokine
SDF-1 enhances circulating CD34(+) cell proliferation in synergy with cytokines: Possible role in progenitor
survival. Blood 2000, 95, 756–768. [PubMed]
77. Nefedova, Y.; Landowski, T.H.; Dalton, W.S. Bone marrow stromal-derived soluble factors and direct cell
contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia 2003, 17,
1175–1182. [CrossRef] [PubMed]
78. Nervi, B.; Ramirez, P.; Rettig, M.P.; Uy, G.L.; Holt, M.S.; Ritchey, J.K.; Prior, J.L.; Piwnica-Worms, D.;
Bridger, G.; Ley, T.J.; et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by
the CXCR4 antagonist AMD3100. Blood 2009, 113, 6206–6214. [CrossRef] [PubMed]
79. Ferrarini, M.; Steimberg, N.; Ponzoni, M.; Belloni, D.; Berenzi, A.; Girlanda, S.; Caligaris-Cappio, F.;
Mazzoleni, G.; Ferrero, E. Ex Vivo dynamic 3-D culture of human tissues in the RCCS™ bioreactor allows
the study of Multiple Myeloma biology and response to therapy. PLoS ONE 2013, 8, e71613. [CrossRef]
80. Antonelli, A.; Noort, W.A.; Jaques, J.; de Boer, B.; de Jong-Korlaar, R.; Brouwers-Vos, A.Z.; Lubbers-Aalders, L.;
van Velzen, J.F.; Bloem, A.C.; Yuan, H.; et al. Establishing human leukemia xenograft mouse models by
implanting human bone marrow-like scaffold-based niches. Blood 2016, 128, 2949–2959. [CrossRef] [PubMed]
81. Johnson, J.I.; Decker, S.; Zaharevitz, D.; Rubinstein, L.V.; Venditti, J.M.; Schepartz, S.; Kalyandrug, S.;
Christian, M.; Arbuck, S.; Hollingshead, M.; et al. Relationships between drug activity in NCI preclinical
in vitro and in vivo models and early clinical trials. Br. J. Cancer 2001, 84, 1424–1431. [CrossRef] [PubMed]
82. Artandi, S.E.; Chang, S.; Lee, S.L.; Alson, S.; Gottlieb, G.J.; Chin, L.; DePinho, R.A. Telomere dysfunction
promotes non-reciprocal translocations and epithelial cancers in mice. Nature 2000, 406, 641–645. [PubMed]
83. Bendre, M.S.; Margulies, A.G.; Walser, B.; Akel, N.S.; Bhattacharrya, S.; Skinner, R.A.; Swain, F.; Ramani, V.;
Mohammad, K.S.; Wessner, L.L.; et al. Tumor-derived interleukin-8 stimulates osteolysis independent of the
receptor activator of nuclear factor-kappaB ligand pathway. Cancer Res. 2005, 65, 11001–11009. [CrossRef]
[PubMed]
Cancers 2017, 9, 29 13 of 15
84. Cacalano, G.; Lee, J.; Kikly, K.; Ryan, A.; Pitts-Meek, S.; Hultgren, B.; Wood, W.; Moore, M. Neutrophil and B
cell expansion in mice that lack the murine IL-8 receptor homolog. Science 1994, 265, 682–684. [CrossRef]
[PubMed]
85. Morton, J.J.; Bird, G.; Keysar, S.B.; Astling, D.P.; Lyons, T.R.; Anderson, R.T.; Glogowska, M.J.; Estes, P.;
Eagles, J.R.; Le, P.N.; et al. XactMice: Humanizing mouse bone marrow enables microenvironment
reconstitution in a patient-derived xenograft model of head and neck cancer. Oncogene 2016, 35, 290–300.
[CrossRef] [PubMed]
86. Belnoue, E.; Pihlgren, M.; McGaha, T.L.; Tougne, C.; Rochat, A.-F.; Bossen, C.; Schneider, P.; Huard, B.;
Lambert, P.-H.; Siegrist, C.-A. APRIL is critical for plasmablast survival in the bone marrow and poorly
expressed by early-life bone marrow stromal cells. Blood 2008, 111, 2755–2764. [CrossRef] [PubMed]
87. Moreaux, J.; Legouffe, E.; Jourdan, E.; Quittet, P.; Rème, T.; Lugagne, C.; Moine, P.; Rossi, J.F.; Klein, B.;
Tarte, K. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and
dexamethasone. Blood 2004, 103, 3148–3157. [CrossRef] [PubMed]
88. Roosnek, E.; Burjanadze, M.; Dietrich, P.Y.; Matthes, T.; Passweg, J.; Huard, B. Tumors that look for their
springtime in APRIL. Crit. Rev. Oncol./Hematol. 2009, 72, 91–97. [CrossRef] [PubMed]
89. Dudek, H.; Datta, S.R.; Franke, T.F.; Birnbaum, M.J.; Yao, R.; Cooper, G.M.; Segal, R.A.; Kaplan, D.R.;
Greenberg, M.E. Regulation of Neuronal Survival by the Serine-Threonine Protein Kinase Akt. Science 1997,
275, 661–665. [CrossRef] [PubMed]
90. Sprynski, A.C.; Hose, D.; Caillot, L.; Reme, T.; Shaughnessy, J.D., Jr.; Barlogie, B.; Seckinger, A.; Moreaux, J.;
Hundemer, M.; Jourdan, M.; et al. The role of IGF-1 as a major growth factor for myeloma cell lines and the
prognostic relevance of the expression of its receptor. Blood 2009, 113, 4614–4626. [CrossRef] [PubMed]
91. Glassford, J.; Rabin, N.; Lam, E.W.; Yong, K.L. Functional regulation of D-type cyclins by insulin-like growth
factor-I and serum in multiple myeloma cells. Br. J. Haematol. 2007, 139, 243–254. [CrossRef] [PubMed]
92. Chapuis, N.; Tamburini, J.; Cornillet-Lefebvre, P.; Gillot, L.; Bardet, V.; Willems, L.; Park, S.; Green, A.S.;
Ifrah, N.; Dreyfus, F.; et al. Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt
activation in acute myeloid leukemia: Therapeutic value of neutralizing anti-IGF-1R antibody. Haematologica
2010, 95, 415–423. [CrossRef] [PubMed]
93. Piddock, R.E.; Abdul-Aziz, A.M.; Auger, M.J.; Bowles, K.M.; Rushworth, S.A. Macrophage Migration
Inhibitory Factor Drives Multiple Myeloma IL-6/8 Pro-Survival Signals in the Tumor Microenvironment.
Blood 2015, 126, 2988–2988.
94. Fan, F.; Vallet, S.; Sattler, M.; Tonon, G.; Bashari, M.H.; Bakiri, L.; Goldschmidt, H.; Wagner, E.F.; Jaeger, D.;
Podar, K. The AP-1 Transcription Factor JunB Promotes Multiple Myeloma (MM) Cell Proliferation, Survival
and Drug Resistance in the Bone Marrow Microenvironment. Blood 2014, 124, 3446–3446. [CrossRef]
95. Hideshima, T.; Nakamura, N.; Chauhan, D.; Anderson, K.C. Biologic sequelae of interleukin-6 induced
PI3-K/Akt signaling in multiple myeloma. Oncogene 2001, 20, 5991–6000. [CrossRef] [PubMed]
96. Wegiel, B.; Bjartell, A.; Culig, Z.; Persson, J.L. Interleukin-6 activates PI3K/Akt pathway and regulates cyclin
A1 to promote prostate cancer cell survival. Int. J. Cancer 2008, 122, 1521–1529. [CrossRef] [PubMed]
97. Herrero, A.B.; Garcia-Gomez, A.; Garayoa, M.; Corchete, L.A.; Hernandez, J.M.; San Miguel, J.; Gutierrez, N.C.
Effects of IL-8 Up-Regulation on Cell Survival and Osteoclastogenesis in Multiple Myeloma. Am. J. Pathol.
2016, 186, 2171–2182. [CrossRef] [PubMed]
98. Schinke, C.; Giricz, O.; Li, W.; Shastri, A.; Gordon, S.; Barreyro, L.; Bhagat, T.; Bhattacharyya, S.;
Ramachandra, N.; Bartenstein, M.; et al. IL8-CXCR2 pathway inhibition as a therapeutic strategy against
MDS and AML stem cells. Blood 2015, 125, 3144–3152. [CrossRef] [PubMed]
99. Shao, N.; Lu, Z.; Zhang, Y.; Wang, M.; Li, W.; Hu, Z.; Wang, S.; Lin, Y. Interleukin-8 upregulates integrin
β3 expression and promotes estrogen receptor-negative breast cancer cell invasion by activating the
PI3K/Akt/NF-κB pathway. Cancer Lett. 2015, 364, 165–172. [CrossRef] [PubMed]
100. Terpos, E.; Politou, M.; Viniou, N.; Rahemtulla, A. Significance of macrophage inflammatory protein-1 alpha
(MIP-1alpha) in multiple myeloma. Leuk. Lymphoma 2005, 46, 1699–1707. [CrossRef] [PubMed]
101. Tsubaki, M.; CKato; Manno, M.; Ogaki, M.; Satou, T.; Itoh, T.; Kusunoki, T.; Tanimori, Y.; Fujiwara, K.;
Matsuoka, H.; et al. Macrophage inflammatory protein-1α (MIP-1α) enhances a receptor activator of nuclear
factor κB ligand (RANKL) expression in mouse bone marrow stromal cells and osteoblasts through MAPK
and PI3K/Akt pathways. Mol. Cell. Biochem. 2007, 304, 53–60. [CrossRef] [PubMed]
Cancers 2017, 9, 29 14 of 15
102. Zaitseva, L.; Murray, M.Y.; Shafat, M.S.; Lawes, M.J.; MacEwan, D.J.; Bowles, K.M.; Rushworth, S.A. Ibrutinib
inhibits SDF1/CXCR4 mediated migration in AML. Oncotarget 2014, 5, 9930–9938. [CrossRef] [PubMed]
103. Voermans, C.; Van Heese, W.; De Jong, I.; Gerritsen, W.; van Der Schoot, C. Migratory behavior of leukemic
cells from acute myeloid leukemia patients. Leukemia 2002, 16, 650–657. [CrossRef] [PubMed]
104. Barbero, S.; Bonavia, R.; Bajetto, A.; Porcile, C.; Pirani, P.; Ravetti, J.L.; Zona, G.L.; Spaziante, R.; Florio, T.;
Schettini, G. Stromal Cell-derived Factor 1α Stimulates Human Glioblastoma Cell Growth through the
Activation of Both Extracellular Signal-regulated Kinases 1/2 and Akt. Cancer Res. 2003, 63, 1969–1974.
[PubMed]
105. Mitsiades, N.; Mitsiades, C.S.; Poulaki, V.; Chauhan, D.; Richardson, P.G.; Hideshima, T.; Munshi, N.;
Treon, S.P.; Anderson, K.C. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma:
Therapeutic applications. Blood 2002, 99, 4079–4086. [CrossRef] [PubMed]
106. Oster, W.; Cicco, N.A.; Klein, H.; Hirano, T.; Kishimoto, T.; Lindemann, A.; Mertelsmann, R.H.; Herrmann, F.
Participation of the cytokines interleukin 6, tumor necrosis factor-alpha, and interleukin 1-beta secreted by
acute myelogenous leukemia blasts in autocrine and paracrine leukemia growth control. J. Clin. Investig.
1989, 84, 451–457. [CrossRef] [PubMed]
107. Smith, M.V.; Lee, M.J.; Islam, A.S.; Rohrer, J.L.; Goldberg, V.M.; Beidelschies, M.A.; Greenfield, E.M. Inhibition
of the PI3K-Akt signaling pathway reduces tumor necrosis factor-alpha production in response to titanium
particles in vitro. J. Bone Jt. Surg. Am. 2007, 89, 1019–1027.
108. Gupta, D.; Treon, S.; Shima, Y.; Hideshima, T.; Podar, K.; Tai, Y.; Lin, B.; Lentzsch, S.; Davies, F.; Chauhan, D.
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth
factor secretion: Therapeutic applications. Leukemia 2001, 15, 1950–1961. [CrossRef] [PubMed]
109. Aguayo, A.; Kantarjian, H.; Manshouri, T.; Gidel, C.; Estey, E.; Thomas, D.; Koller, C.; Estrov, Z.; O’Brien, S.;
Keating, M.; et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000,
96, 2240–2245. [PubMed]
110. Fiedler, W.; Graeven, U.; Ergün, S.; Verago, S.; Kilic, N.; Stockschläder, M.; Hossfeld, D.K. Vascular Endothelial
Growth Factor, a Possible Paracrine Growth Factor in Human Acute Myeloid Leukemia. Blood 1997, 89,
1870–1875. [PubMed]
111. Takahashi, M.; Matsui, A.; Inao, M.; Mochida, S.; Fujiwara, K. ERK/MAPK-dependent PI3K/Akt
phosphorylation through VEGFR-1 after VEGF stimulation in activated hepatic stellate cells. Hepatol. Res.
2003, 26, 232–236. [CrossRef]
112. Miller, T.W.; Rexer, B.N.; Garrett, J.T.; Arteaga, C.L. Mutations in the phosphatidylinositol 3-kinase pathway:
Role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res. 2011, 13.
[CrossRef] [PubMed]
113. Hess, G.; Herbrecht, R.; Romaguera, J.; Verhoef, G.; Crump, M.; Gisselbrecht, C.; Laurell, A.; Offner, F.;
Strahs, A.; Berkenblit, A.; et al. Phase III study to evaluate temsirolimus compared with investigator’s choice
therapy for the treatment of relapsed or refractory mantle cell lymphoma. J. Clin. Oncol. 2009, 27, 3822–3829.
[CrossRef] [PubMed]
114. Choo, A.Y.; Yoon, S.O.; Kim, S.G.; Roux, P.P.; Blenis, J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to
mediate cell-type-specific repression of mRNA translation. Proc. Natl. Acad. Sci. USA 2008, 105, 17414–17419.
[CrossRef] [PubMed]
115. Mothe-Satney, I.; Yang, D.; Fadden, P.; Haystead, T.A.J.; Lawrence, J.C. Multiple Mechanisms Control
Phosphorylation of PHAS-I in Five (S/T)P Sites That Govern Translational Repression. Mol. Cell. Biol. 2000,
20, 3558–3567. [CrossRef] [PubMed]
116. Zhou, J.; Schmid, T.; Frank, R.; Brüne, B. PI3K/Akt is required for heat shock proteins to protect
hypoxia-inducible factor 1α from pVHL-independent degradation. J. Biol. Chem. 2004, 279, 13506–13513.
[CrossRef] [PubMed]
117. Sims, J.D.; McCready, J.; Jay, D.G. Extracellular heat shock protein (Hsp) 70 and Hsp90α assist in matrix
metalloproteinase-2 activation and breast cancer cell migration and invasion. PLoS ONE 2011, 6, e18848.
[CrossRef] [PubMed]
118. Cornford, P.A.; Dodson, A.R.; Parsons, K.F.; Desmond, A.D.; Woolfenden, A.; Fordham, M.; Neoptolemos, J.P.;
Ke, Y.; Foster, C.S. Heat shock protein expression independently predicts clinical outcome in prostate cancer.
Cancer Res. 2000, 60, 7099–7105. [PubMed]
Cancers 2017, 9, 29 15 of 15
119. Kimura, E.; Enns, R.E.; Alcaraz, J.E.; Arboleda, J.; Slamon, D.J.; Howell, S.B. Correlation of the survival of
ovarian cancer patients with mRNA expression of the 60-kD heat-shock protein HSP-60. J. Clin. Oncol. 1993,
11, 891–898. [CrossRef] [PubMed]
120. Chatterjee, M.; Jain, S.; Stuhmer, T.; Andrulis, M.; Ungethum, U.; Kuban, R.J.; Lorentz, H.; Bommert, K.;
Topp, M.; Kramer, D.; et al. STAT3 and MAPK signaling maintain overexpression of heat shock proteins
90alpha and beta in multiple myeloma cells, which critically contribute to tumor-cell survival. Blood 2007,
109, 720–728. [CrossRef] [PubMed]
121. Reikvam, H.; Nepstad, I.; Sulen, A.; Gjertsen, B.T.; Hatfield, K.J.; Bruserud, O. Increased antileukemic effects
in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors. Expert Opin. Investig. Drugs
2013, 22, 551–563. [CrossRef] [PubMed]
122. Ying, W.; Du, Z.; Sun, L.; Foley, K.P.; Proia, D.A.; Blackman, R.K.; Zhou, D.; Inoue, T.; Tatsuta, N.; Sang, J.;
et al. Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and
a Superior Safety Profile for Cancer Therapy. Mol. Cancer Ther. 2012, 11, 475–484. [CrossRef] [PubMed]
123. Yao, Q.; Nishiuchi, R.; Kitamura, T.; Kersey, J.H. Human leukemias with mutated FLT3 kinase are
synergistically sensitive to FLT3 and Hsp90 inhibitors: The key role of the STAT5 signal transduction
pathway. Leukemia 2005, 19, 1605–1612. [CrossRef] [PubMed]
124. Chia, S.; Gandhi, S.; Joy, A.A.; Edwards, S.; Gorr, M.; Hopkins, S.; Kondejewski, J.; Ayoub, J.P.; Califaretti, N.;
Rayson, D.; et al. Novel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the
treatment of breast cancer. Curr. Oncol. 2015, 22, 33–48. [CrossRef] [PubMed]
125. Yang, Q.; Modi, P.; Newcomb, T.; Queva, C.; Gandhi, V. Idelalisib: First-in-Class PI3K Delta Inhibitor for the
Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.
Clin. Cancer Res. 2015, 21, 1537–1542. [CrossRef] [PubMed]
126. Jain, N.; O’Brien, S. Initial treatment of CLL: Integrating biology and functional status. Blood 2015, 126,
463–470. [CrossRef] [PubMed]
127. Agata, Y.; Kawasaki, A.; Nishimura, H.; Ishida, Y.; Tsubat, T.; Yagita, H.; Honjo, T. Expression of the PD-1
antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol. 1996, 8, 765–772. [CrossRef]
[PubMed]
128. Topalian, S.L.; Drake, C.G.; Pardoll, D.M. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor
immunity. Curr. Opin. Immunol. 2012, 24, 207–212. [CrossRef] [PubMed]
129. Patsoukis, N.; Li, L.; Sari, D.; Petkova, V.; Boussiotis, V.A. PD-1 Increases PTEN Phosphatase Activity While
Decreasing PTEN Protein Stability by Inhibiting Casein Kinase 2. Mol. Cell. Biol. 2013, 33, 3091–3098.
[CrossRef] [PubMed]
130. Shepherd, C.; Banerjee, L.; Cheung, C.; Mansour, M.; Jenkinson, S.; Gale, R.; Khwaja, A. PI3K/mTOR
inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response. Leukemia 2013,
27, 650–660. [CrossRef] [PubMed]
131. Serra, V.; Scaltriti, M.; Prudkin, L.; Eichhorn, P.J.A.; Ibrahim, Y.H.; Chandarlapaty, S.; Markman, B.;
Rodriguez, O.; Guzman, M.; Rodriguez, S.; et al. PI3K inhibition results in enhanced HER signaling and
acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene 2011, 30, 2547–2557. [CrossRef]
[PubMed]
132. Balakrishnan, K.; Peluso, M.; Fu, M.; Rosin, N.Y.; Burger, J.A.; Wierda, W.G.; Keating, M.J.; Faia, K.; O’Brien, S.;
Kutok, J.L.; et al. The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib),
overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL. Leukemia 2015, 29,
1811–1822. [CrossRef] [PubMed]
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
